EGFR mutations remain a major challenge in immunotherapy for non‐small cell lung cancer (NSCLC), with poor responses to immune checkpoint inhibitors driven by mechanisms associated with EGFR mutation‐mediated tumor microenvironment (TME) modulation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.